Myasthenia gravis
Conditions
Interventions
Control group:None
Sponsors
The First Affiliated Hospital of China Medical University, Shenyang, China
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Patients voluntarily signed the informed consent form. 2) Diagnosed with generalized myasthenia gravis (gMG) according to the 2020 Chinese Guidelines for the Diagnosis and Treatment of Myasthenia Gravis, meeting the following criteria: Muscle weakness involves ocular, pharyngeal, limb, facial, masticatory, and neck muscles, characterized by fluctuating and fatigable symptoms (i.e., symptoms are milder in the morning and worsen in the evening, exacerbate with sustained activity, and improve with rest). Diagnosis can be established by meeting any two of the following three criteria: a. Positive neostigmine test (quantitative assessment using the Xu's scale) or symptom improvement after oral pyridostigmine bromide; b. Electromyography (EMG) findings: repetitive nerve stimulation (RNS) shows a decremental response of >10% in low-frequency stimulation in at least one nerve, or single-fiber electromyography (SFEMG) reveals increased "jitter" in two or more muscles; c. Serological testing positive for AChR-Ab. 3) Age between 18 and 80 years. 4) Treated with either Telitacicept or conventional immunosuppressants, including glucocorticoids and/or tacrolimus. 5) Completed a follow-up observation period of 12 months.
Exclusion criteria
Exclusion criteria: 1) Ocular myasthenia gravis or myasthenic crisis. 2) Pregnancy or lactation. 3) Any ongoing bacterial or viral infection not treated with antibiotics or antiviral therapy. 4) Use of other targeted therapies or immunosuppressants besides Telitacicept, glucocorticoids, or tacrolimus. 5) Incomplete medical records or loss to follow-up.
Countries
China
Contacts
Public ContactRuixia Zhu
The First Affiliated Hospital of China Medical University, Shenyang, China
Outcome results
None listed